Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

OCS-01

Alternative Names: OCS-01, OCS01
Latest Update: 2025-04-22
Latest Update Note: Clinical Trial Update

Product Description

Oculis is developing OCS-01 as a treatment for diabetic macular edema (DME). (Sourced from: https://oculis.com/pipeline/ocs-01-diabetic-macular-edema/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Oculis
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OCS-01

Countries in Clinic: Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Spain, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Cataract|Inflammation|Macular Edema

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DIAMOND-1

P3

Recruiting

Macular Edema

2026-06-01

DIAMOND-2

P3

Recruiting

Macular Edema

2026-06-01

2021-005173-95

P3

Active, not recruiting

Macular Edema

2025-10-09

DX221

P3

Completed

Macular Edema

2024-07-29

Recent News Events

Date

Type

Title

04/17/2025

News Article

 Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

04/15/2025

News Article

 Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

04/10/2025

News Article

 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

04/01/2025

News Article

 Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

02/01/2023

PubMed

 Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study.

12/01/2022

PubMed

 OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions